Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis

Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-mod...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2018
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22632
Acceso en línea:
https://doi.org/10.1016/j.msard.2018.09.014
https://repository.urosario.edu.co/handle/10336/22632
Palabra clave:
Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
Rights
License
Abierto (Texto Completo)
id EDOCUR2_2b29a399b3fd098991d04120f85e8b61
oai_identifier_str oai:repository.urosario.edu.co:10336/22632
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 59ded4c9-10b6-4b63-928a-2a6f79338dc477f7c241-ad5c-4c20-8027-4346cd7252a8fc8aca80-c009-4364-90f4-2f3cc56f4415c0262846-5226-43f6-8445-4b9ec0a50a9b7914139860080d51910-5fa5-4f27-bb27-9c24085d036f2020-05-25T23:57:13Z2020-05-25T23:57:13Z2018Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018application/pdfhttps://doi.org/10.1016/j.msard.2018.09.01422110348https://repository.urosario.edu.co/handle/10336/22632engElsevier B.V.200192Multiple Sclerosis and Related DisordersVol. 26Multiple Sclerosis and Related Disorders, ISSN:22110348, Vol.26,(2018); pp. 192-200https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053856722&doi=10.1016%2fj.msard.2018.09.014&partnerID=40&md5=56fff51e5923b216bcbec854c32a836aAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAlemtuzumabBeta interferonDaclizumabFingolimodGlatiramerPlaceboTeriflunomideBeta interferonCrotonic acid derivativeImmunologic factorTeriflunomideToluidine derivativeArticleDrug efficacyDrug safetyHumanHypertransaminasemiaLiver functionLiver function testMeta analysisMultiple sclerosisSystematic reviewToxic hepatitisTreatment outcomeComparative studyDrug effectLiverMultiple sclerosisToxic hepatitisChemical and drug induced liver injuryCrotonatesHumansImmunologic factorsInterferon-betaLiverMultiple sclerosisToluidinesInterferon ?Liver safety profileMultiple sclerosisTeriflunomideSafety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysisarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Salas P.A.O.Parra C.O.Florez C.E.P.Goez L.M.Vélez van Meerbeke, Alberto FranciscoRodriguez J.H.10336/22632oai:repository.urosario.edu.co:10336/226322022-05-02 07:37:17.652795https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
title Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
spellingShingle Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
title_short Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
title_full Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
title_fullStr Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
title_full_unstemmed Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
title_sort Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
dc.subject.keyword.spa.fl_str_mv Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
topic Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
description Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018
publishDate 2018
dc.date.created.spa.fl_str_mv 2018
dc.date.accessioned.none.fl_str_mv 2020-05-25T23:57:13Z
dc.date.available.none.fl_str_mv 2020-05-25T23:57:13Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.msard.2018.09.014
dc.identifier.issn.none.fl_str_mv 22110348
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/22632
url https://doi.org/10.1016/j.msard.2018.09.014
https://repository.urosario.edu.co/handle/10336/22632
identifier_str_mv 22110348
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 200
dc.relation.citationStartPage.none.fl_str_mv 192
dc.relation.citationTitle.none.fl_str_mv Multiple Sclerosis and Related Disorders
dc.relation.citationVolume.none.fl_str_mv Vol. 26
dc.relation.ispartof.spa.fl_str_mv Multiple Sclerosis and Related Disorders, ISSN:22110348, Vol.26,(2018); pp. 192-200
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053856722&doi=10.1016%2fj.msard.2018.09.014&partnerID=40&md5=56fff51e5923b216bcbec854c32a836a
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier B.V.
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1808390879133564928